Welcome to LookChem.com Sign In|Join Free
  • or
2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)-propionic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

59686-55-4

Post Buying Request

59686-55-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

59686-55-4 Usage

Molecular weight

323.34 g/mol

Physical form

White to off-white solid

Derivative of

Tyrosine

Common use

In peptide synthesis as a protecting group for the hydroxyl group on the tyrosine amino acid

Industries utilized

Pharmaceutical and biotechnology

Benefits

Protects the reactive hydroxyl group during synthesis

Potential applications

Biomedical research and development.

Check Digit Verification of cas no

The CAS Registry Mumber 59686-55-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,6,8 and 6 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 59686-55:
(7*5)+(6*9)+(5*6)+(4*8)+(3*6)+(2*5)+(1*5)=184
184 % 10 = 4
So 59686-55-4 is a valid CAS Registry Number.

59686-55-4Relevant academic research and scientific papers

Mussel-inspired, perfluorinated polydopamine for self-cleaning coating on various substrates

Hong, Daewha,Bae, Ki Eun,Hong, Seok-Pyo,Park, Ji Hun,Choi, Insung S.,Cho, Woo Kyung

, p. 11649 - 11652 (2014)

We designed a perfluorinated dopamine derivative, which, upon oxidative polymerization, formed a structurally rough film of extremely low surface energy on various substrates. The static water contact angles larger than 150° and the low water sliding angl

Synthesis method of N alpha-t-butyloxycarboryl-DL-m-hydroxy tyrosine

-

Paragraph 0015-0019, (2019/09/17)

The invention relates to a synthesis method of N alpha-t-butyloxycarboryl-DL-m-hydroxy tyrosine, which mainly solves the technical problems that the existing synthesis method is higher in cost and high in pollution, generates many byproducts and is adverse to mass production. The synthesis method comprises the following steps: dissolving DL-m-hydroxy tyrosine in a buffer solution prepared by anhydrous sodium carbonate an anhydrous sodium bicarbonate, performing stirring for intensive dissolution, slowly dropwise adding di-tert butyl dicarbonate mixed solution where acetone is dissolved at 0 DEG C, keeping a pH (pondus hydrogenii) value of a reaction solution to be 8-9 with a sodium carbonate aqueous solution, tracking a reaction endpoint through TLC (thin-Layer chromatography), after a reaction is finished, performing filtration, washing unreacted di-tert butyl dicarbonate in filtrate using an ethyl acetate and petroleum ether mixed solution, adding an extraction agent, ethyl acetate,into a water phase, performing acidification using solid citric acid, controlling the pH value to be 3-5, permitting standing and layering, tracking a byproduct through the TLC, washing an oil phase,performing drying and reduced pressure distillation, and adding petroleum ether for crystallization to form N alpha-t-butyloxycarboryl-DL-m-hydroxy tyrosine. N alpha-t-butyloxycarboryl-DL-m-hydroxy tyrosine is a raw material for synthesizing a polypeptide drug.

NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

-

Page/Page column 91, (2016/06/01)

The invention provides novel compounds having the general formula (I) wherein R1 to R6, W and X are as described herein and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as l-DOPA prodrugs

Giorgioni, Gianfabio,Claudi, Francesco,Ruggieri, Sabrina,Ricciutelli, Massimo,Palmieri, Giovanni F.,Stefano, Antonio Di,Sozio, Piera,Cerasa, Laura S.,Chiavaroli, Annalisa,Ferrante, Claudio,Orlando, Giustino,Glennon, Richard A.

scheme or table, p. 1834 - 1843 (2010/05/02)

l-DOPA, the immediate biological precursor of dopamine, is still considered the drug of choice in the treatment of Parkinson's disease. However, therapy with l-DOPA is associated with a number of acute problems. With the aim to increase the bioavailability after oral administration, we designed a multi-protected l-DOPA prodrugs able to release the drug by both spontaneous chemical or enzyme catalyzed hydrolysis. The new compounds have been synthesized and preliminarily evaluated for their water solubility, log P, chemical stability, and enzymatic stability. The results indicate that the incorporation of the amino acidic moiety of l-DOPA into an imidazoline-4-one ring provides prodrugs sufficiently stable to potentially cross unchanged the acidic environment of the stomach, and to be absorbed from the intestine. They also might be able to release l-DOPA in human plasma after enzymatic hydrolysis. The ability of prodrugs 6a-b to increase basal levels of striatal DA, and influence brain neurochemistry associated with dopaminergic activity following oral administration, as well as the radical-scavenging activity against DPPH for compounds 6a-b and 15a are also reported.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 59686-55-4